Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5EHL4
|
|||
| Drug Name |
Acoramidis
|
|||
| Synonyms |
Acoramidis; AG-10; Acoramidis [USAN]; AG10; 1446711-81-4; T12B44A1OE; 3-[3-(3,5-Dimethyl-1h-Pyrazol-4-Yl)propoxy]-4-Fluorobenzoic Acid; UNII-T12B44A1OE; CHEMBL3940890; 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid; WHO 11205; Benzoic acid, 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluoro-; 4hiq; ACORAMIDIS [INN]; ACORAMIDIS [WHO-DD]; SCHEMBL15816954; BDBM50197885; AKOS040759821; HY-109165; CS-0116350; E79901; Q27451739; 16V
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Transthyretin amyloid cardiomyopathy [ICD-11: 5D00.20; ICD-10: E85.1] | Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17FN2O3
|
|||
| Canonical SMILES |
CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F
|
|||
| InChI |
InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)
|
|||
| InChIKey |
WBFUHHBPNXWNCC-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transthyretin (TTR) | Target Info | Modulator | [2] |
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | Retinoid cycle disease events | |||
| The canonical retinoid cycle in rods (twilight vision) | ||||
| Non-integrin membrane-ECM interactions | ||||
| Retinoid metabolism and transport | ||||
| Amyloid formation | ||||
| WikiPathways | Visual phototransduction | |||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03860935) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AstraZeneca | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.